Toxicity, supportive care and costs of two chemotherapy protocols for treatment of childhood ALL in Russia: BFM 90m and MB 91

European Journal of Cancer

Volumn 35, Issue 9, 1999, Pages 1349-1355

  Von Stackelberg, A ^a   Karatchunsky, A ^b   Kudrjashova, J ^b   Miakova, N ^b   Belikova, L ^b   Rumiantzev, A ^b   Hartmann, R ^a   Henze, G ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b Institute of Paediatric Haematology   (Russian Federation)

Author keywords

Acute lymphoblastic leukaemia; Paediatrics; Toxicity

Indexed keywords

ASPARAGINE; CYTOSTATIC AGENT; DAUNORUBICIN; DEXAMETHASONE; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; VINCRISTINE;

ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CENTRAL NERVOUS SYSTEM; CHILD; CHILDHOOD; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG COST; DRUG TOXICITY; HEALTH CARE COST; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RUSSIAN FEDERATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COSTS AND COST ANALYSIS; ERYTHROCYTE TRANSFUSION; HUMANS; LENGTH OF STAY; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; PLATELET TRANSFUSION; RED-CELL APLASIA, PURE;

EID: 0033197907     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00112-4     Document Type: Article

References (28)

1. Pui C.H., Crist W.M. Biology and treatment of acute lymphoblastic leukemia. J. Pediatr. 124:1994;491-503.
2. Rumiantsev A.G., Samochatova E.V., Karachunsky A.I.et al. Intensive chemotherapy for acute leukemias (AL) in childhood with BFM protocols. Moscow experiences 1990-92. First successes and failures. Haematol. Blood Transfus. 36:1994;344-346.
3. Karatchunsky A, Rumiantzev A, Stackelberg A, et al. Interim results of two childhood ALL regimens in Russia: ALL-BFM 90 and MB 91. Med Pediatr Oncol 1994, 23, 172, (abstract).
4. Karatchunsky A, Rumiantzev A, Stackelberg A, et al. Randomized comparison of two protocols for childhood ALL in Russia: MB 91 and modified ALL BFM 90. Med Pediatr Oncol 1996, 27, 266, (abstract).
5. Schrappe M., Reiter A., Sauter S.et al. Konzeption und zwischenergebnis der therapiestudie ALL-BFM 90 zur behandlung der akuten lymphoblastischen leukämie bei kindern und jugendlichen. die bedeutung des initialen ansprechens in blut und knochenmark Klin. Pädiatr. 206:1994;208-221.
6. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, WHO, 1979, 14-15.
7. Rote Liste 1995, arzneimittelverzeichnis des BPI und VFA; bundesverband der pharmazeutischen industrie e.V., editio Cantor Verlag, Aulendorf/Württ, 1995.
8. Riehm H, Schrappe M, Reiter A, et al. ALL BFM 95, Therapiestudie zur behandlung von kindern und jugendlichen mit ALL. Abteilung Kinderheilkunde IV, Pädiatrische Hämatologie und Onkologie, Medizinische Hochschule Hannover, 1995.
9. Jones B., Freeman A.I., Shuster J.J.et al. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med. Pediatr. Oncol. 19:1991;269-275.
10. Veerman A.J., Hählen K., Kamps W.A.et al. Dutch Childhood Leukemia Study Group. early results of study ALL VI (1984-88) Haematol. Blood Transfus. 33:1990;473-477.
11. Veerman A.J., Hählen K., Kamps W.A.et al. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. results of protocol ALL VI from the Dutch Childhood Leukemia Study Group J. Clin. Oncol. 14:1996;911-918.
12. Lippman M.E., Halterman R.H., Leventhal B.G., Perry S., Thompson E.B. Glucocorticoid-binding proteins in human acute lymphoblastic leukemic blast cells. J. Clin. Invest. 52:1973;1715-1725.
13. Balis F.M., Lester C.M., Chrousos G.P., Heideman R.L., Poplack D.G. Differences in cerebrospinal fluid penetration of corticosteroids. possible relationship to the prevention of meningeal leukemia J. Clin. Oncol. 5:1987;202-207.
14. Kaspers G.J., Pieters R., VanZantwijk C.H.et al. In vitro drug sensivity of normal peripheral blood lymphocytes and childhood leukemic cells from bone marrow and peripheral blood. Br. J. Cancer. 64:1991;469-474.
15. Klumper E., Pieters R., Kaspers G.J.et al. Cytostatic drug resistance in childhood relapsed acute lymphoblastic leukemia. Haematol. Blood Transfus. 36:1994;291-295.
16. Sallan S.E., Hitchcock-Bryan S., Gelber R., Cassady J.R., Frei E., Nathan D.G. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res. 43:1983;5601-5607.
17. Clavell L.A., Gelber R.D., Cohen H.J.et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lympoblastic leukemia. N. Engl. J. Med. 315:1986;657-663.
18. Nesbit M., Karon M., Chard R., Hammond G.D., Evans A. Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am. J. Pediatr. Hematol. Oncol. 1:1979;9-13.
19. Riccardi R., Holcenberg J.S., Glaubiger D.L., Wood J.H., Poplack D.G. L-aparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res. 41:1981;4554-4558.
20. Sullivan M.P., Chen T., Dyment P.G., Hvizdala E., Steuber C.P. Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia. a Pediatric Oncology Group Study Blood. 60:1982;948-958.
21. Littman P., Coccia P., Bleyer W.A.et al. Central nervous system (CNS) prophylaxis in children with low risk acute lymphoblastic leukemia (ALL). Int. J. Rad. Oncol. Biol. Phys. 13:1987;1443-1449.
22. Pullen J., Boyett J., Shuster J.et al. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia. a Pediatric Oncology Group Study J. Clin. Oncol. 11:1993;839-849.
23. Cherlow J.M., Steinherz P.G., Sather H.N.et al. The role of radiation therapy in the treatment of acute lymphoblastic leukemia with lymphomatous presentation. a report from the Children's Cancer Study Group Int. J. Radiat. Oncol. Biol. Phys. 27:1993;1001-1009.
24. Pinkel D., Woo S. Prevention and treatment of meningeal leukemia in children. Blood. 84:1994;355-366.
25. Boos J., Werber G., Verspohl E., Ahlke E., Nowak-Göttl U., Jürgens H. Asparagine-levels in children on E. coli- and Erwinia-Asparaginase therapy. Ann. Hematol. 68(Suppl. 1):1994;A26.
26. Capizzi R.L. Schedule-dependent synergism and antagonism between methotrexate and asparaginase. Biochem. Pharmacol. 2(Suppl. 2):1974;151-161.
27. Ochs J. Neurotoxicity due to central nervous system therapy for childhood leukemia. Am. J. Pediatr. Hematol. Oncol. 11:1989;93-105.
28. Wong K.Y., Lampkin B.C. Anthracycline toxicity. Am. J. Pediatr. Hematol. Oncol. 5:1983;93-97.